Cargando…

Correction to: Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper

Detalles Bibliográficos
Autores principales:	Hox, Valerie, Lourijsen, Evelijn, Jordens, Arnout, Aasbjerg, Kristian, Agache, Ioana, Alobid, Isam, Bachert, Claus, Boussery, Koen, Campo, Paloma, Fokkens, Wytske, Hellings, Peter, Hopkins, Claire, Klimek, Ludger, Mäkelä, Mika, Mösges, Ralph, Mullol, Joaquim, Pujols, Laura, Rondon, Carmen, Rudenko, Michael, Toppila-Salmi, Sanna, Scadding, Glenis, Scheire, Sophie, Tomazic, Peter-Valentin, Van Zele, Thibaut, Wagenmann, Martin, van Boven, Job F. M., Gevaert, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523078/ https://www.ncbi.nlm.nih.gov/pubmed/33005330 http://dx.doi.org/10.1186/s13601-020-00343-w

Ejemplares similares

Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

Diagnostic tools in Rhinology EAACI position paper
por: Scadding, Glenis, et al.
Publicado: (2011)

A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
por: Hellings, Peter, et al.
Publicado: (2015)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
por: Bachert, Claus, et al.
Publicado: (2015)

A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
por: Hellings, Peter W., et al.
Publicado: (2015)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion
por: Bachert, Claus, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
por: Hellings, Peter, et al.
Publicado: (2013)

A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
por: Bousquet, Jean, et al.
Publicado: (2013)

Endoscopic sinus surgery in adult patients with chronic rhinosinusitis with nasal polyps (PolypESS): study protocol for a randomised controlled trial
por: Lourijsen, Evelijn S., et al.
Publicado: (2017)

Identification of gaps in the current allergic rhinitis guidelines and how these can be filled
por: Bousquet, Jean, et al.
Publicado: (2015)

A new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch
por: Fokkens, Wytske, et al.
Publicado: (2015)

The ‘GA²LEN Sinusitis Cohort’: an introduction
por: Vandeplas, Griet, et al.
Publicado: (2015)

Prediction and prevention of allergy and asthma in EAACI journals (2016)
por: Bousquet, Jean, et al.
Publicado: (2017)

Highlights and recent developments in airway diseases in EAACI journals (2017)
por: Bousquet, J., et al.
Publicado: (2018)

A EUFOREA comment on a lost comorbidity of asthma
por: Conti, Diego M., et al.
Publicado: (2023)

ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy
por: Bousquet, Jean, et al.
Publicado: (2021)

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy
por: Calderon, Moises A, et al.
Publicado: (2012)

Highlights and recent developments in allergic diseases in EAACI journals (2019)
por: Bousquet, J., et al.
Publicado: (2020)

Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report
por: Cingi, C., et al.
Publicado: (2017)

Highlights and recent developments in skin allergy and related diseases in EAACI journals (2018)
por: Akdis, C. A., et al.
Publicado: (2019)

ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)
por: Bousquet, Jean, et al.
Publicado: (2020)

Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement
por: Scadding, Glenis K., et al.
Publicado: (2020)

Correction to: Highlights and recent developments in skin allergy and related diseases in EAACI journals (2018)
por: Akdis, C. A., et al.
Publicado: (2020)

Omics technologies in allergy and asthma research: An EAACI position paper
por: Radzikowska, Urszula, et al.
Publicado: (2022)

Capsaicin for Rhinitis
por: Fokkens, Wytske, et al.
Publicado: (2016)

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter]
por: Scadding, Glenis K, et al.
Publicado: (2023)

ERS/EAACI statement on adherence to international adult asthma guidelines
por: Mathioudakis, Alexander G., et al.
Publicado: (2021)

Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?
por: Van Broeck, Dorien, et al.
Publicado: (2023)

COVID‐19 pandemic and allergen immunotherapy—an EAACI survey
por: Pfaar, Oliver, et al.
Publicado: (2021)

The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey
por: Price, David, et al.
Publicado: (2015)

Research needs in allergy: an EAACI position paper, in collaboration with EFA
por: Papadopoulos, Nikolaos G, et al.
Publicado: (2012)

EAACI position paper on occupational rhinitis
por: Moscato, Gianna, et al.
Publicado: (2009)

EAACI Allergen Immunotherapy User's Guide
por: Alvaro‐Lozano, Montserrat, et al.
Publicado: (2020)

Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis
por: Valero, Antonio, et al.
Publicado: (2020)

EAACI anaphylaxis guidelines: systematic review protocol
por: de Silva, Debra, et al.
Publicado: (2020)

Acute and chronic rhinosinusitis and allergic rhinitis in relation to comorbidity, ethnicity and environment
por: Hoffmans, Ruth, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_96s5j55ebhmn886suondimbvrr